次新異動 | 觸底反彈?康方生物-B漲超11%,三天累漲22%
uSMART盈立智投12月7日消息,康方生物-B呈現底部反彈趨勢,截至15:02分,盤中漲超11%,截至目前,康方生物-B已三連漲,累漲22%。
國金證券:給予康方生物-B"買入"評級,目標價36港元
根據公司在研管線核心品種的拆分與估值,國金證券預計公司合理估值爲238億元。派安普利單抗預計2021年獲批上市,預計2020-2022年公司收入額約0.1/4.1/9.8億元,首次覆蓋,給予"買入"評級,目標價爲36港元。
中金:康方生物-B等8只股一個月後有望納入港股通
中金預計一個月後有望納入港股通的公司,包括康希諾生物-B(06185)、啓明醫療-B(02500)、康寧傑瑞製藥-B(09966)、亞盛醫藥-B(06855)、諾誠健華-B(09969)、康方生物-B(09926)、沛嘉醫療-B(09996)、再鼎醫藥-SB(09688)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.